Servier Acquires Day One Biopharmaceuticals for $2.5 Billion

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Mar 06 2026

0mins

Source: PRnewswire

Day One Biopharmaceuticals Inc (DAWN) shares surged 65.96% in pre-market trading, reaching a 52-week high amid the announcement of Servier's acquisition for $2.5 billion.

The acquisition, valued at $21.50 per share, demonstrates Servier's commitment to enhancing its oncology pipeline, particularly in rare cancers. This strategic move aligns with Servier's 2030 ambition to develop innovative therapies for high unmet medical needs, which is expected to close in Q2 2026, providing Day One shareholders with a 68% premium return.

This acquisition not only reflects strong market confidence in Day One's potential but also positions both companies to leverage their combined expertise in delivering innovative cancer treatments, enhancing their competitive edge in the oncology market.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Let AI Trade for You

Auto Trading Task on NVDA?

Get Started Free